Home > Healthcare > Biotechnology > Biotechnology R&D > Hematopoietic Stem Cell Transplantation Market

Hematopoietic Stem Cell Transplantation Market Share

Report ID: GMI6276
Published Date: Jul 2023
Report Format: PDF

Download Free Sample

Hematopoietic Stem Cell Transplantation Market Share

The well known, established, prominent players in hematopoietic stem cell transplantation market are:

Pluristem Therapeutics Inc.
Sanofi
Taiga Biotechnologies, Inc
CellGenix GmbH
Novartis AG
Regen Biopharma Inc.
Kiadis Pharma
Marker Therapeutics, Inc.
Escape Therapeutics, Inc.
GlaxoSmithKline plc
Merck KGaA
Bluebird Bio, Inc.
Talaris Therapeutics.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The Global market size for hematopoietic stem cell transplantation was valued to be USD 2.6 billion in 2022 and is expected to record a CAGR of 9.3% by 2032, owing to the increasing incidence of leukemia, rising success rate of transplantation, and technological advancements.

The autologous transplant therapy segment held the largest market share of 57.6% in 2022 as it reduces the time and resources required for donor search and facilitates a quicker transplantation process.

North America market is expected to reach USD 2.2 billion by 2032 because the region boasts a well-developed and advanced healthcare infrastructure, including specialized transplant centers and comprehensive cancer centers.

Pluristem Therapeutics Inc., Sanofi, Taiga Biotechnologies, Inc., CellGenix GmbH, Novartis AG, Regen Biopharma Inc., Kiadis Pharma, Marker Therapeutics, Inc., Escape Therapeutics, Inc., GlaxoSmithKline plc, Merck KGaA, Bluebird Bio, Inc., and Talaris Therapeutics.